https://www.selleckchem.com/pr....oducts/omaveloxolone
es of Health Research. Bill Melinda Gates Foundation, Canadian Institutes of Health Research. Multiple active vaccination approaches have proven ineffective in reducing the substantial morbidity and mortality caused by respiratory syncytial virus (RSV) in infants and older adults (aged ≥65 years). A vaccine conferring a substantial and sustainable boost in neutralising activity is required to protect against severe RSV disease. To that end, we evaluated the safety and immunogenicity of DS-Cav1, a prefusion F subunit
Like
Comment
Share
